To access this material please log in or register

Register Authorize

Moderate tachycardia in arterial hypertension: A point of application for pulse reducing drugs with antihypertensive activity

Oleynikov V. E., Lykjyanova M. V., Kulyutsin A. V., Gusakovskaya L. I.

Keywords: hyperpiesis, beta-adrenergic blocker agents, tachyarrhythmia, heart rate

DOI: 10.18087/rhj.2014.3.1938

Tachycardia, one of the key markers for autonomic imbalance, plays a critical role in development and progression of AH. Heart rate (HR) is significantly higher in AH patients than in normotensives, which is associated with persistent tachycardia in 31 % of cases. Increased sinus rhythm induced by the sympathetic hyperactivity provides BP elevation and correlates with incidence of LV hypertrophy, high rigidity and reduced compliance of arteries, and increased pulse wave velocity. The increased HR is associated with slower conductivity and increased abnormal automaticity and trigger activity, which result in reduced threshold of ventricular fibrillation. Tachycardia correlated with severity and progression of atherosclerosis. At present time, two drug classes are available, which reduce HR and BP, β-blockers and non-dihydropyridine calcium channel blockers. Expediency of β-blocker administration in AH is ambiguous.
  1. Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study. Arch Intern Med. 1996 Mar 11;156 (5):505–9.
  2. Seccareccia F, Pannozzo F, Dima F et al. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health. 2001;91 (8):1258–1263.
  3. Braunwald E. Expanding indications for beta-blockers failure. N Engl J Med. 2001;344 (22):1711–1712.
  4. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs. 2006;66 (2):133–44.
  5. Jouven X, Empana JP, Schwartz PJ et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005 May 12;352 (19):1951–8.
  6. Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR / trandolapril STudy (INVEST). Eur Heart J. 2008;29 (10):1327–1334.
  7. Kannel WB, Kannel C, Puffenbarger RS et al. Heart rate and cardiovascular mortality. The Framingham Study. Am Heart J. 1987;113 (6):1489–1494.
  8. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet. 2008;372 (9641):817–821.
  9. Benetos A, Adamopoulos C, Bureau JM et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6‑year period. Circulation. 2002;105 (10):1202–1207.
  10. Habib GB. Is heart rate a risk faktor in the general population? Dialog Cardiovask Med. 2001;6:25–31.
  11. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984 Oct 12;226 (4671):180–2.
  12. Perski A, Olsson G, Landou C et al. Minimum heart rate and coronary atherosclerosis: independent relations to global seve­rity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 1992;123 (3):609–616.
  13. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104 (13):1477–1482.
  14. Sajadieh A, Nielsen OW, Rasmussen V et al. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J. 2004 Mar;25 (5):363–70.
  15. Шальнова С. В., Деев А. Д., Оганов Р. Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология. 2005;45 (10):45–50.
  16. Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13 (6 Pt 2):99S-105S.
  17. Моисеев С. В. Симпатическая нервная система и артериальная гипертония: новые подходы к лечению. Клиническая фармакология и терапия. 2002;11 (3):55–60.
  18. Stern MP, Morales PA, Haffner SM, Valdez RA. Hyperdynamic circulation and the insulin resistance syndrome («syndrome X»). Hypertension. 1992;20 (6):802–808.
  19. Zhang J, Kesteloot H. Anthropometric, lifestyle and metabolic determinants of resting heart rate. A population study. Eur Heart J. 1999 Jan;20 (2):103–10.
  20. Julius S, Krause L, Schork NJ et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 1991 Jan;9 (1):77–84.
  21. Janssen I, Katzmarzyk PT, Church TS, Blair SN. The Cooper Clinic Mortality Risk Index: clinical score sheet for men. Am J Prev Med. 2005;29 (3):194–203.
  22. Кобалава Ж. Д., Котовская Ю. В. Артериальная гипертония: ключи к диагностике и лечению. Москва, 2007. – 432с.
  23. Farinaro E, Della Valle E, Ferrantino G. PLasma lipids and cardiovascular risk: lesions in the community. Ann Ital Med Int. 1995 Oct;10 (Suppl): 31S-34S.
  24. Шляхто Е. В. Патогенез гипертонической болезни. – В кн.: Руководство по артериальной гипертонии. Е. В. Шляхто; под ред. Е. И. Чазова, И. Е. Чазовой. – М.: Медиа Медика, 2005. – Гл. 1. – С. 41–60.
  25. Чазова И. Е., Мычка В. Б., Горностаев В. В и др. Церебро­васкулярные осложнения у больных артериальной гипертензией: первичная и вторичная профилактика. Consilium medicum. 2003;5 (2):61–64.
  26. Ponikowski P1, Piepoli M, Chua TP et al. The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. Eur Heart J. 1999 Nov;20 (22):1667–75.
  27. Asmar R, Benetos A, Topouchian J et all. Assessment of Arterial Distensibility by Automatic Pulse Wave Velocity Measurement (Validation and Clinical Application Studies). Hypertension. 1995;26 (3):485–490
  28. Andoh N, Minami J, Ishimitsu T et al. Relationship between markers of inflammation and brachial-ankle pulse wave velocity in Japanese men. Int Heart J. 2006 May;47 (3):409–20.
  29. Sa Cunha R1, Pannier B, Benetos A et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens. 1997 Dec;15 (12 Pt 1):1423–30.
  30. Mitchell GF, Parise H, Benjamin EJ et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43 (6):1239–1245.
  31. Mitchell GF1, Vasan RS, Keyes MJ et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007 Feb 21;297 (7):709–15.
  32. Кушаковский М. С. Гипертоническая болезнь. (Эссенциальная гипертензия). Причины, механизмы, клиника, лечение. – СПб.: Сотис, 1995. – 311 с.
  33. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet. 2002;359 (9311):995–1003.
  34. Rittoo D1, Monaghan M, Sadiq T et al. Echocardiographic and Doppler evaluation of left ventricular hypertrophy and diastolic function in black and white hypertensive patients. J Hum Hypertens. 1990 Apr;4 (2):113–5.
  35. Verdecchia P1, Porcellati C, Reboldi G et a. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001 Oct 23;104 (17):2039–44.
  36. Levy D, Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322 (22):1561–1566.
  37. Остроумова О. Д., Мамаев В. И., Гедгафова С. Ю. и др. Нарушение диастолической функции левого желудочка при эссенциальной артериальной гипертензии. Кардиология. 2001;41 (6):61–64.
  38. Kaplan NM. Evalution of the hypertensive patients. In: Kaplans Clinical Hypertension. – Eighth edition. – Lippincott Williams Wilkins, 2002. – Р. 161–175.
  39. Галявич А. С. Антагонисты кальция при лечении артериальной гипертонии. Руководство по артериальной гипертонии. Под ред. Чазова Е. М. – Медиа Медика, 2005. – С. 634–643.
  40. Lefrandt JD, van Roon AM. Improved Short-Term Blood Pressure Control by treatment with calcium antagonists in patients with mild or moderate hypertension. J Hypertens. 1999;17 (3).
  41. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and morta­lity in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356 (9227):366–372.
  42. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 1998;351 (9118):1755–1762.
  43. Hansson L1, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000 Jul 29;356 (9227):359–65.
  44. Маколкин В. И. Применение бета-адреноблокаторов при гипертонической болезни. Врач. 1999;4:7–8.
  45. Чихладзе Н. М. Место небиволола – β-адреноблокатора третьего поколения – в лечении больных артериальной гипертензией. Трудный пациент. 2013;11 (10):24–30.
  46. Преображенский Д. В., Сидоренко Б. А., Дедова И. С, Тарыкина Е. В. Блокаторы β-адрено­рецепторов в лечении сердечно-сосудистой заболеваний: место карведилола. Кардиология. 2006;47 (12):79–88.
  47. Конради А. О. Бета-блокаторы в лечении артериальной гипертензии – наступило ли время забвения? Артериальная гипертензия. 2006;12 (3):212–215.
  48. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF / AHA / ACP / AATS / PCNA / SCAI / STS Guideline for the diagnosis and mana­gement of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60 (24):e44–e164.
  49. Frishman WH, Sonnen-blick EH. Beta-adrenergic blocking. In: Hursts The Heart. Schlant RС Alexander RW eds. – Mc Graw-Hill, 1994. – Р. 1271–1290.
  50. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354 (9192):1751–1756.
  51. Гиляревский, С. Р. Роль бета-блокаторов в лечении артериальной гипертонии: мнения, доказательства и реальная практика. Лечащий врач. 2008;6:71–74.
  52. Fraker TD Jr, Fihn SD, Gibbons RJ et al. 2007 chronic angina focused update of the ACC / AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation. 2007 Dec 4;116 (23):2762–72.
  53. Wang Y, Zhang MS, Liu Y. Nebivolol treatment improves resistant arterial function and reduces ventricular hypertrophy and angiotensin II in spontaneously hypertension rats. J Renin Angiotensin Aldosterone Syst. 2013 Jun;14 (2):146–55.
  54. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362 (9395):1527–1535.
  55. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364 (9446):1684–1689.
  56. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369 (9557):201–207.
  57. Шилов А. М., Мельник М. В., Авшалумов А. Ш. Бета-адрено­блокаторы III поколения в лечении сердечно-сосудистых заболеваний Лечащий врач. 2010;1:1–7.
  58. Карташева Е. Д., Линчак Р. М. Роль β-адрено­блокаторов в лечении и профилактике сердечно-сосудистых заболеваний: акцент на карведилол. Трудный пациент. 2010;8 (5):21–27.
  59. Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005;46 (6):1309–1315.
  60. Национальные рекомендации по диагностике и лечению метаболического синдрома. Кардиоваскулярная терапия и профилактика. Приложение 2. 2007;6 (6):22.
  61. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowe­ring effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27 (12):841–849.
  62. Briasoulis A1, Oliva R, Kalaitzidis R et al. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul;15 (7):473–9.
  63. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52 (18):1482–1429.
  64. Fyhrquist F, Dahlöf B, Devereux RB et al. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension. 2005 Apr;45 (4):580–5.
  65. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113 (9):1213–1225.
  66. Леонова М. В. Роль повышения ЧСС в развитии артериальной гипертензии и ее исходов: место β-блокаторов. Русский медицинский журнал. 2014;2:152–157.
Oleynikov V. E., Lykjyanova M. V., Kulyutsin A.V. et al. Moderate tachycardia in arterial hypertension: A point of application for pulse reducing drugs with antihypertensive activity. Russian Heart Journal. 2014;77 (3):179–186

To access this material please log in or register

Register Authorize
Ru En